November 23, 2017 | English | عربي
Add to Twitter
 
Boehringer Ingelheim and MiNA Therapeutics to Develop Novel Treatment Approaches for Fibrotic Liver Diseases
● Collaboration and licensing agreement focused on investigating up to three targets and has a potential transactional value of up to EUR 307 million, excluding royalties

● Expands Boehringer Ingelheim’s comprehensive R&D programme in non-alcoholic steatohepatitis (NASH) and fibrotic liver disease with innovative novel treatment modalities

● Leverages MiNA’s leading expertise in RNA activation therapeutics, evaluating the platform technology’s potential to prevent disease progression by restoring normal cell and target organ function